ICU Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
February 27, 2024 at 09:11 pm
Share
ICU Medical, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 587.86 million compared to USD 578.01 million a year ago. Net loss was USD 17.15 million compared to USD 15.54 million a year ago.
Basic loss per share from continuing operations was USD 0.71 compared to USD 0.65 a year ago. Diluted loss per share from continuing operations was USD 0.71 compared to USD 0.65 a year ago.
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needle free IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy product include Portex BLUselect PVC tracheostomy tubes.